tbuckley/cabot-search huggingface dataset:
AB1162 RAPID3 score can predict disease activity in primary sjÖgren's syndrome
Authors: B Öz, A Karatas, Z Ömercikoğlu, O Catak, N Gozel, S Cur, E Donder, SS Koca
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Sjögren9s syndrome (SS) is a chronic autoimmune disease that causes salivary and lacrimal gland dysfunction, resulting in oral and ocular dryness. The European League Against Rheumatism (EULAR) SS disease activity index (ESSDAI) is a systemic disease activity index measuring disease activity in patients with SS. The ESSDAI includes 12 domains. EULAR SS patient-reported index (ESSPRI) is used to evaluate dryness, fatigue, and pain symptoms, and their impact on the disease. Routine Assessment of Patient Index Data 3 (RAPID3) is used to evaluate disease activity in patients with rheumatoid arthritis which is another inflammatory disorder. <h3>Objectives</h3> This study aims to evaluate whether RAPID3 is useful in primary SS. <h3>Methods</h3> 30 patients with primary SS were enrolled in the study. ESSDAI, ESSPRI and RAPID3 scores were recorded. Chi-square, Mann Whitney U test and Pearson correlation analysis were performed for the statistical analysis. <h3>Results</h3> Demographically and clinical data were shown in the Table-1. Mean ESSDAI, ESSPRI and RAPID3 scores were 3.8±3.6, 5.8±1.7, and 14.8±5.2, respectively. RAPID3 scores were positively correlated ESSPRI (r=0.669, p&lt;0.001). In addition, when we set the cut-off value to 12 on the RAPID3 score (&gt;12 accepted as active, and ≤12 accepted as inactive), ESSPRI score was significantly higher in active patients (6.4±1.4 vs. 4.1±1.4, p=0.002). However, there was no relationship between RAPID3 and ESSDAI scores. Schirmer test was positively correlated with tear break up time (BUT) (r=0.573, p=0.007). Lissamine green score was negatively correlated with Schirmer test and BUT (r=-0.484, p=0.007, and r=-0.507, p=0.004, respectively). Despite there was high compliance among these three scales evaluating eye involvement, these scales did not appear to correlate with the ESSDAI, ESSPRI, and RAPID3 scores that assess global disease activity. The mean age was significantly higher in patients with Schirmer test ≤5 mm compared to the patients with &gt;5 mm (55.6±6.9 vs. 47.6±8.5 years, p=0.044). <h3>Conclusions</h3> In SS, it is not simple to detect disease activity. Comorbid psychosomatic diseases affect the set detecting global disease activity. On the other hand, the activity of glandular involvement and global disease activity are not with compliance. Therefore, new and easy tools are necessary in primary SS. In our study, RAPID3 score is corelated with ESSPRI. This result suggests that RAPID3 is useful to detect disease activity in primary SS. <h3>Disclosure of Interest</h3> None declared
AB0321 Relationship of carotid femoral pulse wave velocity with age and time of evolution in patients with rheumatoid arthritis
Authors: C Ramos, G Alanis, D Cardona, S Totsuka, E Cardona, F Pérez, A Coldivar, J Gόmez, M Vázquez del Mercado
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Early vascular aging occurring in Rheumatoid Arthritis (RA) may be a consequence of chronic inflammation. The measurement of Carotid-femoral pulse wave velocity (cfPWV) is the gold standard to evaluate arterial stiffness. Vascular aging is a result of a change in the biomechanical properties of the vascular wall. This process can be accelerated by the accumulated damage of high mechanical stress (high blood pressure), chronic inflammation and comorbidities such as smoking, Diabetes Mellitus and dyslipidemia<sup>1</sup> <h3>Objectives</h3> The aim of this study was to evaluate variations in the Carotid-Femoral Pulse Wave Velocity (cfPWV) and it9s association to age and time of disease evolution in patients with rheumatoid arthritis. <h3>Methods</h3> RA patients were matched for age and sex with healthy controls. Subjects with a history of smoking, cardiovascular disease, hypertension, diabetes mellitus, cancer, liver disease, thyroid disease and kidney disease were excluded. The cfPWV was calculated using the Pulse Pen ® (Diatechne, Italy) device. <h3>Results</h3> We included 76 women with RA and 28 healthy women, mean age (44.3±10.92 vs. 43.0±16.26, P=0.654). cfPWV demonstrated good correlation with age (r=0.459, P&lt;0.01), disease evolution time (r=0.311, P=0.008), triglycerides (r=0.289, P=0.03), total cholesterol (r=0.421, P&lt;0.01) and atherogenic index (r=0.320, P=0.02). No association with disease activity was found. cfPWV was higher in those patients with RA &gt;10 years evolution compared to patients with &lt;10 years of disease evolution and to controls (P&lt;0.05). <h3>Conclusions</h3> A significant association between cfPWV was seen in patients with RA, and was also correlated to age and to a disease evolution &gt;10 years long without finding a significant association with increased disease activity. <h3>References</h3> -Kozakova M, Morizzo C, Guarino D, et al. The impact of age and risk factors on carotid and carotid-femoral pulse wave velocity. Journal of hypertension 2015;33(7):1446–51 doi: 10.1097/HJH.0000000000000582 [published Online First: Epub Date]|. <h3>Disclosure of Interest</h3> None declared
SAT0751-HPR The relationship between anaerobic exercise capacity and isometric lower extremity muscle strength in children with juvenile idiopathic arthritis
Authors: D Bayraktar, S Savci, E Manci, O Altug-Gucenmez, B Makay, N İlcin, SE Unsal
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is a chronic disease that occurs before the age of 16 years. It was shown that anaerobic exercise capacity, which is important for most daily activities in children such as jumping, hoping and climbing was diminished in JIA. Previous studies showed that anaerobic exercise capacity was related to well-being level, functional status, and aerobic exercise capacity in JIA. However, no data is available about the relationship between lower extremity muscle power and anaerobic exercise capacity in children with JIA. <h3>Objectives</h3> To determine the possible relationships between lower extremity muscle strength and anaerobic capacity. <h3>Methods</h3> Forty-six children with JIA (14 F, 32 M), with a mean age of 13.74±2.29 years (min-max: 9–17 years) were included in the study. Isometric lower extremity muscle strength was assessed with a hand-held dynamometer at the end points of knee flexion, knee extension, hip flexion and hip extension movements, which are generated from gross lower extremity muscles and important for anaerobic power. All the muscle testing was performed on the right leg. Anaerobic exercise capacity was measured performing a 30-second Wingate test. Both absolute and per kilogram values for peak power and average power were noted. The relationships between the parameters were determined with Pearson9s correlation coefficient. (Relationship levels were interpreted as 0.05–0.30: low correlation; 0.30–0.40: low-moderate correlation; 0.40–0.60: moderate correlation; 0.60–0.75: good correlation; 0.75–1.00: good-excellent correlation. <h3>Results</h3> All children completed the assessments without any adverse effects. Demographics, average isometric lower extremity muscle strengths and parameters related to the anaerobic exercise capacity testing were shown at Table 1. Moderate to good correlations were determined between isometric muscle strength and anaerobic exercise capacity parameters p&lt;0.001 (Table 2). <h3>Conclusions</h3> The results of this study suggested that lower extremity muscle strength might influence the anaerobic exercise capacity. Exercise regimes including lower extremity strengthening might help improving anaerobic exercise capacity in children with JIA. <h3>Disclosure of Interest</h3> None declared
AB1017 The defeat of the hip joint in ankylosing spondylitis by magnetic resonance imaging
Authors: E Agafonova, T Dubinina, A Dyomina, O Rumiantceva, D Rumiantceva, M Podryadnova, A Starkova, S Krasnenko, M Urumova, S Erdes
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> According to the carried out epidemiological studies in Russia of patients with ankylosing spondylitis (AS) defeat of the hip joints was impairment in 46% of cases, but was the reason for the replacement in 7% of cases. i <h3>Objectives</h3> To compare the clinical manifestations of hip arthritis (coxitis) with the results of magnetic resonance imaging (MRI) of the hip joints (HJ) in patients with ankylosing spondylitis (AS). <h3>Methods</h3> Examined 117 patients (mean age 31,7±12.7 y meeting modified N-Y criteria), with complaints of pain in the hip joints. The average age of onset of disease was 26.3±20.3 years, HLA-B27 identified in 93% of patients. The median duration of AS – 57 [2–384] months. BASDAI 5,7±3,1. Diagnosis of hip septic arthritis were made based on clinical signs - the presence of pain in hips and/or restriction of movements in HJ at the time of patient admission to the clinic. In addition to clinical and radiographic examination all patients were performed MRI modes T1 and STIR. Results: The Median duration of clinical manifestations of coxitis by the time of the study was 60 months. [25‰; 75‰], evaluation of pain in HJ for numeric rating scaler (NRS) – 4 [2; 8]. According to MRI identified the following inflammatory changes (IC): synovitis-71 (83%) patients, bone marrow edema (BME)- 44 (31,6%) patients (BME acetabulum 36%, BME heads 63%), a combination of synovitis and BME were 7 patients (9%). Depending on radiological stage (estimated by BASRI hip), patients were divided into two groups (table 1). <h3>Results</h3> <h3>Conclusions</h3> MRI allows to clarify the cause of the pain and limitations of movement in HJ with AS, determine the patient has inflammatory changes, including in the absence of radiographic changes in these joints. Patients with severe radiological change (BASRI II-IV), have a greater duration of the disease, severe functional abnormalities in the BASFI index. With increasing radiological stage (BASRI hip II-IV) increased the detection rate of osteitis by MRI. Further research to clarify the relationship of clinical manifestations of coxitis (pain level) from MRI data. <h3>Disclosure of Interest</h3> None declared
THU0542 Anti-interleukin 1 therapy in FMF amyloidosis: a single center experience (case series)
Authors: S Ugurlu, B Ergezen, A Hacioglu, H Ozdogan
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Recently there is increasing number of reports investigating the efficacy of anti-interleukin-1 (anti-IL1) therapy in AA-amyloidosis. <h3>Objectives</h3> Here we report our experience in IL-1 blockade in AA amyloidosis secondary to FMF. <h3>Methods</h3> Twenty nine FMF patients with secondary AA-amyloidosis with insufficient response to colchicine were treated with anti-IL-1 agents (canakinumab and anakinra). Creatinine (Cre), 24-hour urine protein (UP), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured before and throughout the treatment to evaluate the response and side effects. <h3>Results</h3> Twenty nine (16 female, 13 male) patients with FMF-related amyloidosis were administered anti-IL1 agents (12 on canakinumab, 17 on anakinra) in addition to colchicine in 27 patients, with a mean dose of 1.4±0.6 mg/day. The mean age was 40.13±11.76, while the mean duration of FMF was 28.79±10.51 years. The mean follow-up was 13.92±11.31 months for anakinra and 11.82±9.92 months for canakinumab. Initial Cre levels were less than 1.5 mg/dl in 13 patients (range 0.37-.5). In this subgroup proteinuria decreased significantly from 3739.87±4860.41 to 1321.45±2015.62 mg/day while Cre was stable (0.91±0.30 mg/dl to 1.04±0.39 mg/dl) and acute phase response was normalized (CRP from 6.16±7.86 mg/l to 5.20±9.64 mg/l, ESR from 27.3±18.63 to 14±8.04).In the second group there were 11 patients with initial Cre levels higher than 1.5mg/dl (range 1.73–3.76). Proteinuria decreased from 6321.66±5936.43 to 4827.55±6264.43 mg/day, Cre increased from 2.53±0.76 to 3.07±1.70mg/dl, while there was a decrease in the APR in this subgorup (CRP from 40±64.65 mg/l to 26.71±26.76 mg/l, ESR from 57.37±37.65 to 39.11±27.72). There are two patients on hemodialysis whereas two underwent renal transplantation. Global patient assessment score of the whole group was decreased from 7.44±2.54 to 3.89±3.53 with anti-IL-1. Anakinra was stopped in 11 and canakinumab in 3 patients, due to irresponsiveness in 8 and 2 patients respectively. Among patients in whom anakinra was terminated 9 were later treated with canakinumab. Twenty four patients are still recieving anti-IL-1treatment (16 on anakinra, 8 on canakinumab). <h3>Conclusions</h3> Anti IL-1 treatments seems to be effective and safe in the treatment of AA amyloidosis secondary to FMF. The beneficial effect of this approach is more pronounced in patients with creatinine levels of less that 1.5 mg/dl. <h3>Disclosure of Interest</h3> None declared
Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Rubén A. Bartolomé, Carmen Aizpurua, Marta Jaén, Sofía Torres, Eva Calviño, Juan I. Imbaud, J. Ignacio Casal
Journal: Clinical Cancer Research (2017)

Purpose: New targets are required for the control of advanced metastatic disease. We investigated the use of cadherin RGD motifs, which activate the α2β1integrin pathway, as targets for the development of therapeutic monoclonal antibodies (mAb).Experimental Design: Cadherin 17 (CDH17) fragments and peptides were prepared and used for immunization and antibody development. Antibodies were tested for inhibition of β1 integrin and cell adhesion, proliferation, and invasion assays using cell lines from different cancer types (colorectal, pancreatic, melanoma, and breast cancer). Effects of the mAbs on cell signaling were determined by Western blot analysis. Nude mice were used for survival analysis after treatment with RGD-specific mAbs and metastasis development.Results: Antibodies against full-length CDH17 failed to block the binding to α2β1 integrin. However, CDH17 RGD peptides generated highly selective RGD mAbs that blocked CDH17 and vascular-endothelial (VE)-cadherin-mediated β1 integrin activation in melanoma and breast, pancreatic, and colorectal cancer cells. Antibodies provoked a significant reduction in cell adhesion and proliferation of metastatic cancer cells. Treatment with mAbs impaired the integrin signaling pathway activation of FAK in colorectal cancer, of JNK and ERK kinases in colorectal and pancreatic cancers, and of JNK, ERK, Src, and AKT in melanoma and breast cancer. In vivo, RGD-specific mAbs increased mouse survival after inoculation of melanoma and colorectal cancer cell lines to cause lung and liver metastasis, respectively.Conclusions: Blocking the interaction between RGD cadherins and α2β1 integrin with highly selective mAbs constitutes a promising therapy against advanced metastatic disease in colon cancer, melanoma, and, potentially, other cancers. Clin Cancer Res; 24(2); 433-44. ©2017 AACRSee related commentary by Marshall, p. 253.
Cervical soft tissue recurrence of differentiated thyroid carcinoma after thyroidectomy indicates a poor prognosis
Authors: Luying Gao, Yuxin Jiang, Zhiyong Liang, Lei Zhang, Xinxin Mao, Xiao Yang, Ying Wang, Jingzhu Xu, Ruyu Liu, Shenling Zhu, Ruina Zhao, Xingjian Lai, Xiaoyan Zhang, Bo Zhang
Journal: International Journal of Surgery (2017)
OP0169 Early osteophytes detected by mri are associated with changes in knee pain and structures in older adults: a population-based cohort study
Authors: Z Zhu, LL Laslett, W Han, B Antony, F Cicuttini, G Jones, C Ding
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Early stage of osteophyte (OP) formations are hard to be detected by radiography, but can be detected by magnetic resonance imaging (MRI). Their subsequent developments on structural and clinical abnormalities are still unknown. <h3>Objectives</h3> To describe the prevalence of early osteophytes (OPs) that were detected by magnetic resonance imaging (MRI) but not by X-ray in older adults and to evaluate the longitudinal associations with knee pain and structural changes. <h3>Methods</h3> 837 participants (mean age 62 years, 50% female) were randomly selected from local community at baseline. T1- or T2-weighted fat suppressed MRI was used to assess knee OPs, cartilage volume, cartilage defects and bone marrow lesions (BMLs) at baseline and after 2.6 years. Knee pain was assessed by self-administered Western Ontario and McMaster Osteoarthritis (WOMAC) Index questionnaire at baseline and after 5 years. X-ray-detected OPs were assessed at baseline using the Osteoarthritis Research Society International atlas. OPs detected only by MRI but not by standard X-ray were defined as early OPs. OPs detected by both MRI and X-ray were defined as definite OPs. <h3>Results</h3> The prevalence of early OPs was 75% while the prevalence of definite OPs was 10% in total knee at baseline. Compared with participants without any OPs, participants with early OPs and with definite OPs had greater cartilage volume loss and increased cartilage defects and BMLs over 2.6 years. Presence of early medial tibiofemoral OPs predicted decreases in total knee pain over 5 years, while definite OPs predicted increases in total knee pain, after adjustment for relevant covariates. <h3>Conclusions</h3> Although early OPs are associated with knee abnormal structural changes, they predict decreases in knee pain over time suggesting an adaptive response. <h3>References</h3> Centers for Disease C, Prevention. Public health and aging: projected prevalence of self-reported arthritis or chronic joint symptoms among persons aged &gt;65 years–United States, 2005–2030. MMWR Morb Mortal Wkly Rep 2003; 52: 489–491. <h3>Acknowledgements</h3> The authors thank the participants who made this study possible, and acknowledge the role of the staff and volunteers in collecting the data, particularly research nurses Boon C and Boon P. Warren R assessed MRIs and Dr Srikanth V and Dr Cooley H assessed radiographs. <h3>Disclosure of Interest</h3> None declared
THU0339 Fecal calprotectin levels as an indicator of active disease in behÇet's syndrome patients with gastrointestinal involvement: a controlled study
Authors: SN Esatoglu, I Hatemi, Y Ozguler, G Hatemi, H Uzun, AF Celik, H Yazici
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Elevated fecal calprotectin (FC) levels indicate activity in Crohn9s disease (CD) and ulcerative colitis and are used as non-invasive biomarkers in these diseases. Gastrointestinal involvement of Behçet9s syndrome (GIBS) shows clinical and endoscopic similarities to CD. A previous study suggested that FC may help to diagnose GIBS patients (1), but we are not aware of any studies addressing its role in identifying disease activity in such patients. <h3>Objectives</h3> To determine whether FC helps to distinguish active GIBS patients from those in remission. <h3>Methods</h3> We collected fecal and serum specimens before colonoscopy from 39 GIBS patients who agreed to participate (Table). Twenty-six patients were asymptomatic whereas 13 had abdominal pain and/or diarrhea. We also filled disease activity index for intestinal Behçet9s disease (DAIBD) and Crohn9s disease activity index (CDAI) in each patient. Active gastrointestinal (GI) involvement was defined as having ulcers on colonoscopy. We included 22 active and 25 inactive CD patients as controls. We used 150 μg/g as the cut-off for a positive FC level. None of the patients were receiving NSAIDs that could increase FC levels. <h3>Results</h3> Among the 39 GIBS patients, 14 had active ulcers on colonoscopy (8/13 symptomatic and 6/26 of asymptomatic). FC level was &gt;150 μg/g in 12/14 active GIBS patients and in 6/25 patients in GI remission (OR: 19, 95% CI: 3 to 110). The median FC and CRP levels were higher among active GIBS patients whereas serum calprotectin levels were not different (Table). Among CD patients, 16/25 active patients and 3/22 patients in remission had a FC level &gt;150 μg/g (OR: 11, 95% CI: 11 to 49). There was a high correlation between FC and CDAI scores (r=0.64, p&lt;0.001) and a very high correlation between FC and DAIBD scores (r=0.71, p&lt;0.001), while FC was not correlated with serum calprotectin and CRP levels. Among the 6 GIBS patients who had high FC levels despite being in remission for GI involvement, 2 had active mucocutaneous lesions, 1 had concomitant macrophage activation syndrome (MAS), 1 had polycythemia vera with trisomy 8 and 2 were started high dose corticosteroids. Repeat FC levels could be obtained in 3 of these patients, after the resolution of MAS and mucocutaneous lesions, and were &lt;150 in all 3. <h3>Conclusions</h3> FC seems to be a useful non-invasive tool for identifying active GI involvement in GIBS patients. Whether the presence of other BS manifestations can cause false positive results in GIBS patients in remission remains to be studied. On the other hand, serum calprotectin levels do not seem to be useful in identifying active disease in GIBS patients. <h3>References</h3> Kim DH et al. J Gastroenterol Hepatol. 2016. <h3>Disclosure of Interest</h3> None declared
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe
Authors: N.I. Cherny, R. Sullivan, J. Torode, M. Saar, A. Eniu
Journal: Annals of Oncology (2017)

The availability and affordability of safe, effective, high-quality, affordable anticancer therapies are a core requirement for effective national cancer control plans.
New NHS safety watchdog aims to promote openness and avoid “blame culture”
Authors: Clare Dyer
Journal: BMJ (2017)

A new independent patient safety watchdog for the NHS in England aims to tackle the “blame culture” that critics say hampers the health service in learning lessons to prevent future harm to patients.

The Health Service Safety Investigations Body (HSSIB) is modelled on bodies that investigate air and marine safety, where there is a focus on risks to the public rather than apportioning blame to individuals. It will cover NHS commissioned services in England, including those provided by GPs.

The body, to be given statutory powers under a parliamentary bill introduced on 14 September,1 will create a “safe …